Guardant Health Reports First Quarter 2026 Financial Results
Guardant Health, Inc. reported a total revenue of $301.7 million for the first quarter of 2026, representing a 48% increase compared to the same period in 2025. The oncology revenue was $205.0 million, up 36%, with approximately 86,000 oncology tests conducted, marking a 47% increase.
PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: Reported total revenue of $301.7 million, an increase of 48%, driven by: Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47%